iCardio.ai

We are excited to be deepening our relationship with Cedars-Sinai as iCardio.ai joins the 10th accelerator cohort at The Cedars-Sinai Accelerator! https://lnkd.in/gZqHkEvN Roman Sandler Aakriti Gupta, MD MSc Omar Perez Nirdesh K Gupta, PhD Julien Brohan Samantha Shobash Gabriel Shaya MD, MPH Min-Yi Shih David Yakobi, MD Benjamin Wessler Aleksandar Stojmenski Markos Muche Robert Luxenberg

We are pleased to announce our partnership with Viz.ai, one of the biggest and fastest growing medical AI companies in the world. With Viz, we will be advancing the care of patients living with aortic stenosis. A huge congrats to the team and all involved! Joseph Sokol, Aakriti Gupta, MD MSc, Roman Sandler, Aleksandar Stojmenski, Matt Longo, Carla Sananez, et al!

📣 Did someone say the United State of AI? 🤝 deepc welcomes iCardio.ai to the deepcOS Radiology AI platform and looks forward to further unlocking the full potential of AI in transforming cardiac care together. Our shared vision for a future where technology and healthcare seamlessly intertwine has now begun. Stay tuned for how our partnership will shape the future of cardiology and expand the horizons of what's possible in medical diagnostics. #iCardioAI #DeepC #Innovation #CardiacCare #HealthTech #AI #Partnership #FutureOfHealthcare

🎗️ Celebrating Heart Valve Disease Awareness Day with a Breakthrough! 🚀 Bonus: Can you read the case? Answer below! ⬇ Today, on Heart Valve Disease Awareness Day, we at iCardio.ai are more inspired than ever to reflect on our recent landmark achievement: receiving the FDA Breakthrough Device Designation for our pioneering Aortic Stenosis detection technology. Just yesterday, we shared the incredible news that has positioned us at the forefront of cardiac care innovation. 🩺❤️ This designation marks a historic moment, not only for our dedicated team at iCardio.ai but for heart health globally. It underscores the critical importance of early detection and treatment of heart valve diseases, such as Aortic Stenosis, which affects millions worldwide. Our technology promises to revolutionize the way we approach the diagnosis and management of heart valve conditions, making early detection a reality for many. Why is this moment so pivotal? - Our FDA Breakthrough Designation comes at a time when raising awareness and understanding of heart valve disease is more crucial than ever. It highlights the urgent need for innovative solutions like ours that can lead to early detection and treatment, potentially saving lives. - As we celebrate Heart Valve Disease Awareness Day, let's spotlight the significance of advancements in medical technology that can address such critical health issues. Our technology not only facilitates early diagnosis but also embodies our commitment to healthcare equity, ensuring that cutting-edge medical solutions are accessible to all. - This achievement is a testament to the hard work and dedication of our incredible team and our partners, including Butterfly Network, Inc. Together, we are setting new standards in cardiac care, paving the way for a future where heart valve disease is detected and treated early on, improving outcomes for patients worldwide. - As we honor this important day, we are reminded of the impact that innovation, collaboration, and dedication can have on transforming healthcare. Our journey is just beginning, and we are excited about the potential to contribute to the fight against heart valve disease. - To everyone who has supported us and to those who share our vision for a healthier future, thank you. We are just getting started. 💪❤️ #HeartValveDiseaseDay #iCardioAI #FDA #BreakthroughDesignation #AorticStenosis #CardiacCareInnovation #HealthEquity #EarlyDetection #SaveLives Answer: The ultrasound clip below shows an AI-predicted case of severe Aortic Stenosis!

🚀 Exciting Milestone Alert: iCardio.ai Achieves FDA Breakthrough Designation for Aortic Stenosis Detection! 🩺 We are thrilled to share iCardio.ai has been granted Breakthrough Device Designation by the FDA for our Aortic Stenosis screening product! This designation is for detection of Aortic Stenosis in settings outside the echo lab, such as in the primary care setting. Most importantly, to our knowledge, this is the **FIRST** FDA Breakthrough Designation for anything to do with POCUS/handheld ultrasound devices. This is not just a win for our dedicated team; it's a giant leap forward in cardiac care globally. 🌍❤️ Why is this a game-changer? 1. Aortic Stenosis is a critical heart condition that affects approximately 1.5 million Americans. Early detection and treatment are vital, and our technology promises to fill crucial diagnostic gaps, enabling more effective treatments and potentially saving lives. 2. Our technology offers hope for early and accurate diagnosis, facilitating timely interventions, and challenging traditional detection methods. With our partnership with Butterfly Network, Inc., we're set to massively distribute this life-saving technology, reaching primary care settings and underserved populations previously out of reach. 3. The FDA's Breakthrough Designation not only accelerates our path to commercial use but also underscores our potential to increase TAVR procedures, driving significant revenue for tertiary centers. 4. Our technology also stands to reduce disparities in healthcare by providing a standardized, unbiased diagnostic tool that can be widely deployed across various healthcare settings and demographics. This aligns with the broader mission of promoting health equity and ensuring that advancements in medical technology benefit all segments of society. 5. Breakthrough Designation puts us towards a path to reimbursement through New Technology Add-on Payment (NTAP), and we anticipate the reimbursement will drive massive adoption in the use of handheld ultrasound. 🚀 With this designation, our momentum is stronger than ever. If you are interested in learning more about our journey, please reach out to us on our website: https://icardio.ai. This accomplishment was a true team effort, in no particular order thank you: Aakriti Gupta, MD MSc, Benjamin Wessler, Roman Sandler, Gabriel Shaya MD, MPH, David Yakobi, MD, Aleksandar Stojmenski, Golnaz (Naz) Moeini, Judith Buckland, Davinder Ramsingh MD, John Martin, MD, MBA, and so many others!!! #iCardioAI #FDA #BreakthroughDesignation #AorticStenosis #HealthcareInnovation #InvestmentOpportunity #MachineLearning #UltrasoundTechnology

Our group enjoyed working on this collaboration with iCardio.ai. We demonstrate how to implement a multi-AI concurrent ultrasound workflow in real-time on NVIDIA Holoscan.

📢 MAJOR NEWS 📢 iCardio.ai and UltraLinQ Healthcare Solutions have partnered to bring AI for Ultrasound to the masses. This partnership intends to distribute iCardio.ai's suite of AI tools to the thousands of institutions UltraLinQ serves across the United States and worldwide. Given the size of UltraLinQ's footprint, this commercial development represents one of the largest in the AI medical imaging world. The news coverage can be found here: https://lnkd.in/g3DBRXfY This is extremely significant for several reasons, here's just a few for brevity: 1. Every UltraLinQ end-user will get iCardio.ai's tools. Not electively, but by standard install anytime a clinic signs up, or if they are already signed up, to use UltraLinQ as their PACs. 2. AI has been traditionally sold institution to institution, one at a time, making commercial traction in this industry slow or even entirely impractical. Partnering with UltraLinQ will bring iCardio.ai to thousands of institutions. By comparison, Aidoc and Viz.ai have reached unicorn-billion-dollar valuations with distribution to institutions far fewer. 3. Understanding that the image interaction happens on the PACs, UltraLinQ's forward-thinking team intends to capitalize on that interaction by adding an AI layer. This partnership is the first true attempt I've seen in the industry of building the PAC system of the future; (and not just another app store, which among the day-to-day activities of busy healthcare practitioners receives little attention). AI will now be a part of the standard clinical workflow in a meaningful way. 4. We are proving a brand new business model by approaching the medical world as a software company. The iCardio.ai API can a) be integrated to make any PACs system more valuable, b) augment and free time from already-burdened physicians, and c) impact millions of patients' lives. A huge CONGRATULATIONS to both the iCardio.ai and UltraLinQ teams for pioneering this unique partnership!